The competitor of Neuralink, the brain implant startup founded by Elon Musk, Synchron, has announced that it has launched an online registration platform for patients interested in participating in its trials.

According to Reuters, the trial may involve dozens of participants, and approximately 120 clinical trial centers have expressed interest in assisting with the research.

"We are excited to launch a community-centered Brain-Computer Interface (BCI) registration platform," said Tom Oxley, CEO and founder of Synchron. "BCI is sparking a grassroots movement. We are creating a pathway for potential users and their doctors to participate and stay connected, while also preparing for the next phase of clinical trials."

Based in New York, Synchron has reportedly made more progress in testing its brain implant technology compared to Neuralink. Both companies focus on enabling paralyzed patients to type on computers using devices that decode brain signals.

Synchron received authorization for its preliminary tests in July 2021 and has since implanted its devices in six patients. The company reported no serious side effects in an early trial involving four patients conducted in Australia.

The neurotechnology company is analyzing data from the United States to prepare for broader research and is awaiting approval from the U.S. Food and Drug Administration to advance its work, according to Oxley.

In January of this year, Musk successfully implanted a wireless brain-computer interface chip in the first human patient, achieving a significant milestone. The implanted device reportedly detected "promising neural pulses" from the patient. Subsequently, the patient was able to move a computer mouse and play online chess solely through thoughts.

Who owns Synchron?

Synchron has received support from billionaire investors Jeff Bezos and Bill Gates and competes with Neuralink in the specialized field of brain-computer interface (BCI) devices. These devices either penetrate the brain or sit on its surface to communicate directly with computers through electrodes. So far, no company has obtained final approval from the U.S. Food and Drug Administration to sell BCI brain implants.

The device is implanted into the surface of the brain through a simple procedure using a blood vessel in the neck. Once in place, it senses the brain's movement signals and wirelessly transmits them, aiming to enable severely paralyzed patients to control devices such as computers solely through thoughts, without the need for hands.